Sulministro de Etelcadetida (DOE), Romiplostim (DOE), Panitumumab (DOE), Darbepoetina Alfa (DOE) Y Inebilizumab (DOE)

Deadline:N/A

Contract award

Estimated value
€9,909,185.52
Duration
5 years
Bidders
Awarded bidders
Name
AMGEN, S.A.